Mirum Pharmaceuticals, Inc. financials

MIRM CIK 0001759425

Source: EDGAR filings · Built 2026-06-02T03:33:04Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 54.87M 9.33M -71.05M -120.41M -132.78M -89.30M
EBITDA 2.11M -63.98M -98.33M -127.98M -172.82M -103.99M
Working Capital 343.88M 266.24M 300.48M 125.50M 124.00M 217.89M
Net Debt 22.77M 95.26M 21.82M -25.82M -28.73M -138.82M
Operating Margin -4.25% -26.00% -58.57% -170.28% -906.12%
Net Margin -4.48% -26.10% -87.68% -176.05% -438.85%
Return on Equity (ROE) -7.42% -38.97% -65.72% -95.51% -69.87% -60.01%
Return on Assets (ROA) -2.77% -13.11% -25.27% -38.44% -28.50% -42.87%
Current Ratio 2.67× 3.10× 4.45× 2.94× 3.91× 12.80×
Debt-to-Equity 1.02× 1.41× 1.24× 0.02× 0.02× 0.02×
Effective Tax Rate -9.04% -1.19% -0.61% 4.51% -0.04% -0.01%
Cash Conversion Ratio -2.39× -0.12× 0.43× 0.89× 1.58× 0.86×
Accruals Ratio -0.09× -0.15× -0.14× -0.04× 0.17× -0.06×
SBC % of Revenue 13.70% 14.38% 18.79% 35.05% 120.63%
CapEx Coverage 58.52× 10.40× -650.86× -432.14× -5531.58× -395.89×
Free Cash Flow Per Share $1.09 $0.20 $-1.74 $-3.54 $-4.38 $-3.54

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/FCF 72.26× 210.54×
FCF Yield 1.38% 0.47%
EV / EBITDA 1955.44×
P/S 7.86× 5.93× 7.40× 9.35× 25.49×
P/B 13.03× 8.86× 5.55× 5.07× 4.06× 3.02×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 521.31M 336.89M 186.37M 77.06M 19.14M
Revenues 19.14M 0
Selling, General and Administrative Expense 257.03M 202.22M 145.88M 89.07M 59.22M
Operating Expenses 543.45M 424.49M 295.53M 208.28M 192.55M 104.30M
Operating Income (Loss) -22.14M -87.61M -109.15M -131.22M -173.41M -104.30M
Income Tax Expense (Benefit) 1.94M 1.03M 991.00K -6.41M 37.00K 6.00K
Net Income (Loss) Attributable to Parent -23.36M -87.94M -163.41M -135.66M -83.99M -103.27M
Earnings Per Share, Basic $-0.47 $-1.85 $-4.00 $-4.01 $-2.77
Weighted Average Number of Shares Outstanding, Basic 50.20M 47.52M 40.89M 33.84M 30.32M
Earnings Per Share, Diluted $-0.47 $-1.85 $-4.00 $-4.02 $-2.77
Weighted Average Number of Shares Outstanding, Diluted 50.20M 47.52M 40.89M 33.98M 30.32M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 296.68M 222.50M 286.33M 28.00M 31.34M 142.09M
Assets, Current 549.68M 392.79M 387.54M 190.22M 166.59M 236.35M
Assets 842.81M 670.75M 646.62M 352.91M 294.65M 240.86M
Liabilities, Current 205.80M 126.55M 87.06M 64.73M 42.60M 18.46M
Liabilities 528.12M 445.11M 397.95M 210.87M 174.44M 68.77M
Stockholders' Equity Attributable to Parent 314.69M 225.64M 248.67M 142.04M 120.21M 172.09M
Common Stock, Shares, Outstanding 51.90M 48.34M 46.72M 36.96M 30.58M 29.78M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 55.83M 10.32M -70.94M -120.14M -132.76M -89.08M
Payments to Acquire Property, Plant, and Equipment 954.00K 993.00K 109.00K 278.00K 24.00K 225.00K
Net Cash Provided by (Used in) Investing Activities -23.95M -90.13M -107.20M 7.70M 48.55M 37.87M
Net Cash Provided by (Used in) Financing Activities 40.14M 17.70M 336.60M 109.09M 73.47M 181.29M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (MIRM CIK 0001759425), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

NCLH

NORWEGIAN CRUISE LINE HOLDINGS LTD.

VMD

Viemed Healthcare, Inc.

DOCS

Doximity, Inc.